Nextcure presents preclinical data for nc762 at american association for cancer research (aacr) annual meeting 2021

Beltsville, md., april 10, 2021 (globe newswire) -- nextcure, inc. (nasdaq: nxtc), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today presented preclinical and investigational new drug (ind)-enabling data for nc762 at the american association for cancer research (aacr) annual meeting 2021. nc762 is a humanized monoclonal antibody specific for b7-h4 and is being developed for the treatment of cancer.
NXTC Ratings Summary
NXTC Quant Ranking